Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells

DOI: 10.1016/j.stem.2024.04.018

Authors: Tengku Ibrahim Maulana; Claudia Teufel; Madalena Cipriano; Julia Roosz; Lisa Lazarevski; Francijna E. van den Hil; Lukas Scheller; Valeria Orlova; André Koch; Michael Hudecek; Miriam Alb; Peter Loskill

Step 1: iPSC/ESC maintainance

day 0 ~ 1 (duration missing in database; assumed 1 day)

culture “adherent” human PSC in “E8”. For ECM, use “Vitronectin” at “N/A” “N/A”.

Ideally, “PSC” should express “OCT3/4”, “SSEA-4”, “NANOG” at the end of culture.

Step 2: endothelial 1

day 1 ~ 2 (duration missing in database; assumed 1 day)

culture “unspecified method” human PSC in “unspecified medium”.

Ideally, “EC” should express “PECAM1”, “ROR1”, “CDH5” at the end of culture.